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Abstract  
INTRODUCTION 
We investigated the analytical performance, outlier rate, carryover and reference interval of the 
Beckman Coulter Access hsTnI in detail and compared it with historical and other commercial 
assays.  
MATERIALS AND METHODS 
We compared the imprecision, detection capability, analytical sensitivity, outlier rate and carryover 
against two previous Access AccuTnI assay versions. We established the reference interval with 
stored samples from a previous study and compared the concordances and variances with the Access 
AccuTnI+3 as well as with two commercial assays. 
RESULTS 
The Access hsTnI had excellent analytical sensitivity with the calibration slope 5.6 times steeper 
than the Access AccuTnI+3. The detection capability was markedly improved with the SD of the 
blank 0.18-0.20ng/L, LoB 0.29-0.33ng/L and LoD 0.58-0.69ng/L. All the reference interval samples 
had a result above the LoB value. At a mean concentration of 2.83ng/L the SD was 0.28ng/L (CV 
9.8%). Carryover (0.005%) and outlier (0.046%) rates were similar to the Access AccuTnI+3. The 
combined male and female 99th percentile reference interval was 18.2ng/L (90% CI 13.2-21.1ng/L). 
Concordance amongst the assays was poor with 16.7%, 19.6% and 15.2% of samples identified by 
all 4 assays as above the 99th, 97.5th and 95th percentiles. Analytical imprecision was a minor 
contributor to the observed variances between assays. 
CONCLUSION 
The Beckman Coulter Access hsTnI assay has excellent analytical sensitivity and precision 
characteristics close to zero. This allows cTnI measurement in all healthy individuals and the 
capability to identify numerically small differences between serial samples as statistically 
significant. Concordance in healthy individuals remains poor amongst assays. 
Keywords: cardiac troponin, analytical sensitivity, detection capability, reference interval, 
concordance  
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1 Introduction 
Cardiac troponins I and T (cTnI, cTnT) are well established as the first choice biomarkers to detect 
myocardial insults. Over the past decade there has been a rapid improvement of the detection 
capability that has resulted in improved analytical precision at very low concentrations. The 
purported advantages of these “high sensitivity” (hs) assays include detection of cTnI and cTnT in 
the majority of cardiac-healthy individuals with better risk stratification and improved diagnostic 
sensitivity that may lead to better clinical outcomes. The Beckman Coulter Access hsTnI is a recent 
addition to this category of hs assays and brief evaluations of the method have been published (1, 2). 
We investigated the analytical performance characteristics, outlier rate and carryover of this assay in 
detail and compared it with two historical versions of cTnI assays from the same manufacturer. We 
also determined the reference intervals on stored samples of a previous study (3) and compared the 
concordances with the Access AccuTnI+3 and two commercial hs assays.     
2 Materials and methods 
2.1 Samples and analytical methodology 
We used serum samples obtained from venous blood collected into serum separator tubes (Becton 
Dickinson) and centrifuged at 3000g for 10 minutes after clotting. Pooled sera with target cTnI 
concentrations were used in the precision and carryover experiments. Aliquots were frozen at -80oC 
and were centrifuged for 10 min at 3000g after thawing and analysed within 4 hours. The Access 
hsTnI reference intervals were determined from aliquots collected for a previous study and stored at 
-80oC (3). All the frozen samples were thawed once only before analysis. The protocol was 
approved by the local ethical review board.  
The Access hsTnI assay was performed on a single Beckman Coulter DxI600 analyser 
(Beckman Coulter, Brea, CA) and the same lot of reagent, calibrators and controls were used 
throughout the study. We used archived Access AccuTnI and AccuTnI+ 3 data from previous studies 
to compare analytical sensitivity and short term repeatability (3, 4). The results from a previously 
published reference interval study measured with the Access AccuTnI+3, Abbott Architect STAT 
High Sensitive Troponin-I (Architect hs-TnI) and the Cobas Elecsys TroponinT high sensitive 
(Elecsys TnT-hs) assays were used to assess concordance of troponin results in a healthy cohort. 
The claimed limits of the blanks (LoB) for these assays were: 4ng/L, 0.7-1.3ng/L, and 3ng/L 
respectively (3).  
2.2 Study design and statistical procedures 
2.2.1 Analytical sensitivity and detection capability  
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The calibration slopes of three Access generations (hsTnI, AccuTnI+3 and AccuTnI) were 
constructed with the relative light unit (RLU) raw data signals. We previously performed this 
procedure with the AccuTnI and AccuTnI+3 assays to obtain uncensored results (3, 4). The Access 
hsTnI data were obtained from the precision and reference interval experiments described below. 
The detection capability parameters - standard deviation of the blank (SDBlank), LoB and limit of 
detection (LoD) - were determined with two complementary approaches (7). We repeatedly 
analysed a blank sample (reagent diluent) and estimated the parameters with an abbreviated protocol 
(single lot number and calibrator). The LoB and LoD were estimated with a parametric approach 
with =0.05 (z=1.645). We also estimated the parameters by extrapolation of the imprecision 
profile data obtained from pooled patient samples with low cTnI concentrations (7).   
2.2.2 Analytical imprecision  
We performed a nested ANOVA model experiment with three levels of commercial quality control 
material (Biorad) and with 9 serum pools (5). The serum pools were constructed to extend the 
coverage at low concentrations. The EP05-A3 protocol was modified to 40 runs over 11 days 
instead of 20 days due to time constraints. In addition we also estimated the short term repeatability 
(SDR) for the Access hsTnI from the duplicate results obtained from the reference interval data set in 
5ng/L incremental bins to gain a better appreciation of the imprecision at low concentrations than 
could be obtained with a single QC material. We compared this with data generated for previous 
studies with the Access AccuTnI and AccuTnI+3 assays (3, 6).  
2.2.3 Carryover  
We examined carryover contamination by repeatedly analysing a pooled serum sample with a low 
cTnI concentration immediately before and after a challenge sample as previously described (8). 
The sample with the extremely high cTnI concentration (±750 000ng/L) was submitted for routine 
cTnI analysis post cardiac surgery.  
2.2.4 Outlier rate  
We detected outliers with duplicate analysis of samples as previously described and used a 
probability of 0.0001 (z=3.5) (6). 
2.2.5 Comparison between the Acces hsTnI and the AccuTnI+3  
We analysed 100 routine serum samples with both the Access hsTnI and AccuTnI+3 assays. The 
samples were selected based on the AccuTnI+3 result to cover the expected range of routine cTnI 
results. 
2.2.6 Reference interval 
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We estimated the Access hsTnI reference interval by analysing 1832 stored frozen samples in 
duplicate (647 females and 1185 males). We excluded 172 of the original study participants due to 
insufficient sample volume. We used only the first result to calculate the non-parametric 99th 
percentile reference intervals with 90% confidence intervals (Analyse-it version 2.30). The 
reference intervals of the Access AccuTnI+3, Architect hs-TnI and the Elecsys TnT-hs were also 
recalculated after exclusion of participants with missing Access hsTnI data.  
2.2.7 Concordances amongst assays in the reference population 
We sequentially assessed the concordances of the Access AccuTnI+3, Architect hs-Tn and Elecsys 
hs-TnT relative to the Access hsTnI at specific percentiles as previously described (3). The excess 
variance components, not attributable to imprecision of the assays, were estimated from the 
standard deviation of the differences (SD Differences) between methods and their respective within-
laboratory imprecisions (SDWL). 
3 Results 
3.1 Analytical sensitivity and detection capability  
The calibration curves slopes of three Access assay generations in Figure 1 graphically illustrates 
the progressive improvement in analytical sensitivity that manifested as improved detection 
capability and imprecision at low concentrations. The slopes of the Access AccuTnI+3 and the 
Access hsTnI increased by factors of 1.6 and 8.6 respectively, compared to the original Access 
AccuTnI assay. The directly determined SDBlank was 0.18ng/L with an estimated LoB of 0.29ng/L 
and a LoD of 0.58ng/L. We corroborated this with the complimentary precision profile approach 
by plotting the SDWL obtained with pooled sera followed by extrapolation: SDBlank 0.20ng/L, LoB 
0.33ng/L, LoD 0.69ng/L and LoQ10% 2.75ng/L. All the Access hsTnI results in the reference 
interval study were higher than the theoretical LoB and therefore significantly different from zero. 
The lowest result obtained was 0.4ng/L in a female subject with the next lowest result of 0.6ng/L 
in a male subject. The rest of the results were 0.8ng/L and above. 
3.2 Analytical imprecision 
The Access hsTnI imprecision data are presented in Figure 1 and in Supplementary Table 1. The 
lowest serum pool, with a mean cTnI concentration of 2.83ng/L, had an SDWL of 0.28ng/L and a 
9.9% coefficient of variation (CV).  This compared favourably with our historically determined 
SDWL of 1.76ng/L at a mean concentration of 2.61ng/L (CV 67.5%) for the Access AccuTnI+3. The 
short term imprecision (SDR) of three of Access cTnI generations illustrate the progressive 
improvement in imprecision at low concentrations (Figure 1). In the lowest bin (<5ng/L) the SDR of 
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the Access hsTnI assay (0.16ng/L) was 4.5 fold lower than those of the Access AccuTnI+3 
(0.72ng/L) and approximately 10 times better than the AccuTnI (1.62ng/L).  
3.3 Carryover  
The carryover experiment demonstrated clinically significant carryover similar to those previously 
reported (8) with previous generations of Access assays (Supplementary Table 2). Although the 
carryover fraction is small (0.005%), a result of 44.1ng/L was observed immediately after the 
challenge sample compared to the expected mean of 2.72ng/L. The increased day 2 mean cTnI 
determined on fresh aliquots indicated that contamination of the reagent pack occurred.  
3.4 Outlier rate  
We observed 2 outliers in 4336 possible events with an outlier rate of 0.046% (95% CI 0.01-
0.17%) which is significantly lower than the 0.44% (95%CI 0.25-0.63%) reported for the AccuTnI 
(6) and similar to the 0.025% (95% CI 0.00-0.14%) for the AccuTnI+3 assay (3). 
3.5 Comparison against the AccuTnI+3  
A comparison of a 100 samples ranging up to approximately 30 000ng/L was performed and the 
slope  of the Access hsTnI relative to the Access AccuTnI+3 assay was 0.85 (95% CI 0.83 to 0.89) 
(Supplementary Figure 1). Trimming the range to below than a 100ng/L did not materially affect 
the slope (0.80; 0.73 to 0.89). 
3.6 Reference interval 
The non-parametric 99th percentile reference intervals with 90% confidence intervals are 
summarised in Table 1. The median age of 647 female participants was 33.6 years and ranged 
from 18.0 to 80.4 years. The median age of 1185 males was 43.9 years with a range between 18.0 
and 79.1 years. The 99th percentiles of males (20.88 90%CI 16.32-25.77) and females (9.57 
90%CI 7.34-16.26) differed significantly with no overlap of their confidence intervals. The 
regression of cTnI against age revealed small and gradual increases in the median cTnI of 
0.22ng/L/decade (95%CI 0.18-0.25ng/L) in females and 0.35ng/L/decade (95%CI 0.30-0.40ng/L) 
in male participants (Figure 2).  
 The 99th percentiles determined with in this study compared well with those previously 
determined despite the exclusion of 114 male and 58 female participants (9). Although the 
numeric differences of the female 99th percentiles for the Access AccuTnI+3 and Architect hs-TnI 
assays appeared numerically large, the 90% confidence intervals were overlapped. Using the 
Architect hs-TnI cut-off value from this study (12.7ng/L) on the original cohort we identified 9 
subjects compared to the 6 above the original 20.2ng/L cut-off. The proportions were not 
significantly different (9 vs. 6 in 705 females, p 0.439). The results for the Access AccuTnI+3 
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were similar with 2 additional individuals in the original cohort identified by the lower cut-off 
from this study (p 0.645). 
3.7 Concordances amongst assays in the reference population 
The concordances of the Access AccuTnI+3, Architect hs-TnI and Elecsys hs-TnT assays relative 
to the Access hsTnI were below 60% at the 99th and 95th percentiles (Supplementary Table 3). The 
poor concordance between the Access hsTnI and AccuTnI+3 was particularly notable and was 
approximately 50% even at the 75th percentile. The concordance between the duplicate Access 
hsTnI results served as a reference mark for the isolated impact of analytical imprecision and was 
approximately 95% at all the percentiles tested. Of the potential maximum 18 individuals above 
the 99th percentile only 3 (16.7%) were identified by all four assays. At the 97.5th and 95th 
percentiles only 19.6% and 15.2% were identified. This did not materially improve if restricted to 
the Access hsTnI Architect hs-TnI and Elecsys TnT–hs assays: 22.2%, 23.9% and 20.7%. The 
poor concordances are graphically illustrated in the plots of ranks in Figure 3. This non-parametric 
representation is scale invariant and allows easy inspection of the concordance across the 
measuring ranges. The ranks values were distributed in a near random pattern due to discordant 
results at all levels and not only at the higher percentiles. A result at the upper reference interval 
with one method could have a paired result with another method anywhere, even at the lower end 
of the spectrum. This observation was particularly notable in the comparison with the Access 
AccuTnI+3, but was valid for all combinations. 
 The almost random distribution of results was also evident from scatter and difference 
plots in Figure 4.  Above 10ng/L the results were widely scattered with no clustering around the 
regression lines and with R2 between 0.16 and 0.25. Variance component analysis of the observed 
and predicted differences demonstrated that imprecision of the assays were not major contributors 
to this phenomenon with the estimated sample-method specific variance component the dominant 
contributor (Table 2). The plots of the Access hsTnI duplicate data in Figures 3 and 4 serve as a 
reference for the isolated effect of imprecision on concordance and the distribution of results.    
4 Discussion 
The Access hsTnI assay demonstrates an impressive advance in analytical sensitivity compared to 
the Access AccuTnI+3. The calibration slope increased approximately six fold with excellent 
detection capability and imprecision at low concentrations. Our LoB estimates of 0.29 to 0.33ng/L 
were lower than the 0.8 to 1.7ng/L of Budd (1) and may be explained by our modified protocol of a 
single analyser and one lot of reagents and calibrators. Lippi reported an even lower LoB of 
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0.14ng/L (2) and differences in methodology may again be responsible. This variability amongst the 
studies however illustrates the flaw of using analytical performance characteristics, such as LoB or 
LoD, as clinical decision levels. 
The Access hsTnI regression slope (0.80 to 0.85) may be due to different antibodies and/or a 
change in calibration material. The proportional bias could not fully explain the 99th percentiles that 
were 52 to 63% those of the AccuTnI+3. Antibodies that react with different epitopes may 
contribute to the poor correlation and wide scatter at low concentrations. The scale of the redesign 
was highlighted by the marked discordance between two assay versions from the same manufacturer 
which was comparable with the discordance with other manufacturers. The robustness, as assessed 
by carryover (Supplementary Table 1) and outlier rates were similar to our previous estimates with 
the AccuTnI+3 and probably reflect the mechanical characteristics of the analysers and not the assay 
formulations.  Laboratories and clinicians must therefore continue to be alert about the existence of 
these potential sources of error and should implement procedures to minimize their clinical impact.  
The poor agreement of cardiac troponin results obtained in healthy individuals was a 
prominent feature of this study. This was characterised by suboptimal correlation coefficients, the 
dominant contribution of sample-method specific bias to the observed between method variances 
and in the discordant classification at clinically important percentiles. This raised a number of 
aspects with regard to the clinical use of cardiac troponin assays and reference intervals. Firstly it 
reinforces the critical importance of serial measurements and dynamic change in suspected acute 
coronary syndrome. The improved analytical precision of the Access hsTnI assay will allow 
identification of small numerical differences with a high degree of confidence. At a mean cTnI of 
5.0ng/L a delta greater than 0.8ng/L will exceed the 95% confidence level for analytical significance 
(p 0.05). The biological variation of cTnI measured with the Access hsTnI has not been determined, 
but on the assumption of a 1.5ng/L physiological variation in an individual, the reference change 
value would be approximately 4.2ng/L at a mean cTnI of 5.0ng/L (10).  
The high degree of discordance also argues against the notion that subclinical cardiac 
disease should be excluded with extensive (and expensive) screening of reference interval subjects. 
In our opinion it is possible that the majority of results in the upper range of the population 
distribution with any of the current assays do not reflect “true” concentrations and we hypothesize 
that the sample-method specific bias component may in part explain the severely right skewed 
distributions. With approximately 20% of results concordant above the 99th percentile, it is in our 
opinion a tenuous argument to infer structural cardiac disease in most participants from our cohort 
above this threshold. 
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The 99th percentile upper reference limits of male and female participants with their non-
overlapping confidence intervals raises the role of sex specific reference intervals in clinical 
practice. The small, but statistically significant, difference between male and female age related 
increments may also be invoked to further support this argument. The relatively small increase in 
median cTnI with age does not however correspond with the numerically larger jumps in age related 
99th percentiles that we (3) and others have previously reported. Although the 99th percentile limits 
of males and females may differ numerically with a degree of statistical significance, the low 
density of data points in the vicinity of the 99th percentiles (Figure 2), the  and the analytical 
uncertainty that surrounds the majority of these points may in part explain the questionable benefits 
derived from sex specific reference intervals (9). 
The impressive improvements in the analytical sensitivity, detection capability and 
analytical imprecision of hs assays has not resolved the sample-method specific bias as is evident 
from the discordances and poor correlations. The underlying mechanism of this variance component 
is unclear and should be the focus of future assay development as both accurate and precise 
quantitation may contribute to better risk stratification. 
5. Conclusion 
In conclusion, the new Beckman Coulter Access hsTnI assay has excellent analytical sensitivity and 
imprecision close to zero. This allows cTnI detection in all healthy individuals and the capability to 
identify numerically small differences between serial samples as statistically significant. Despite 
these improvements the concordance and correlation amongst assays in healthy individuals remains 
poor. 
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Tables 
Table 1. Cardiac troponin non-parametric 99th percentile reference intervals (ng/L). 
 
Access hsTnI AccuTnI+3 Architect hs-TnI Elecsys TnT-hs  
Female (n=647) 
Median  1.91 1.58 1.80 1.49 
99th percentile 9.57 18.45 12.72 9.58 
90% CI 7.34 to 16.26 9.53 to 33.00 9.40 to 26.00 8.47 to 10.57 
Male (n=1185) 
Median  2.95 3.06 2.90 3.51 
99th percentile 20.88 33.08 37.22 17.83 
90% CI 16.32 to 25.77 25.00 to 57.50 26.71 to 44.04 15.65 to 19.37 
Combined (n=1832) 
Median  2.54 2.53 2.50 2.68 
99th percentile 18.19 30.65 28.64 15.80 
90% CI 13.18 to 21.07 25.17 to 36.98 22.90 to 44.10 14.55 to 18.11 
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Table 2. Variances of difference components determined for the Access hsTnI vs. the AccuTnI+3, 
Architect hs-TnI and Elecsys TnT-hs assays. 
 AccuTnI+3 Architect hs-TnI Elecsys TnT-hs 
Predicted SD differences 1.89 0.79 1.42 
Observed SD differences 4.90 5.19 2.95 
Sample-method bias SDWL  4.52 5.13 2.59 
All the parameters are in ng/L. 
 The predicted variance for each method pair was calculated from their respective analytical 
imprecisions at approximately 10 to 15ng/L. The imprecisions used in the estimations were: 
Access hsTnI 0.6ng/L, AccuTnI+3 1.8ng/L, Architect hs-TnI  0.55ng/L and Elecsys TnT-hs 1.3 
ng/L. The data for the Architect hs-TnI and the Elecsys TnT-hs assays were obtained from their 
package inserts. 
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Figure legends 
Figure 1. Analytical sensitivity and detection capability of the Access hsTnI assay.  
Top panel: Calibration curves of successive assay generations.  
Middle panel: The estimation of the blank SD by extrapolation of the within laboratory precision 
(SDWL).  
Bottom panel: Repeatability (SDWL) of three assay generations calculated from duplicate results in 
5ng/L bins.  
The 95% confidence intervals are indicated by the error bars.   
Figure 2. Access hsTnI results as a function of age in male and female volunteers.  
The median cTnI results show a proportional increase with age in male and female subjects (solid 
lines). The non-parametrically determined 99th percentiles are indicated by the dotted lines. Please 
note the non-linear cTnI scale on the Y-axis.  
Figure 3. Distributions of the rank values obtained with the Access hsTnI compared with those 
from the Access AccuTnI+3, Architect hs-TnI and Elecsys TnT-hs assays.  
The results the reference interval samples as determined with each assay were ranked and those of 
the three comparative assays were plotted against the Access hsTnI. The plot of the duplicate 
Access hsTnI ranks serve as a reference for the effect of analytical imprecision on the distribution of 
the ranks in this sample set. The lines of identity are indicated in black. Pearson correlation 
coefficients were calculated from the rank values. 
Figure 4. Comparisons of the Access hsTnI with the AccuTnI+3, Architect hs-TnI and Elecsys 
TnT-hs assays in the reference sample set.  
The data from 1832 samples analysed in the reference interval study are presented. The plots of 
the duplicate Access hsTnI results serve as a reference for the effect of analytical imprecision. 
Pearson correlation coefficients were calculated from the numerical results. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Fig 1.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Fig 2.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Fig 3.  
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Highlights 
 The Access hsTnI has excellent analytical sensitivity and detection capability. 
 Troponin was detected in all healthy individuals. 
 The 99th percentile was 18.2ng/L (90%CI 13.2-21.1ng/L). 
 Concordances amongst assays were 20% at the 95th 97.35th and 99th percentile. 
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